Ma Jingxin, Wei Qi, Cheng Xin, Zhang Jie, Zhang Zhongtao, Su Jianrong
Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center of Digestive Diseases, Beijing, China.
Front Pharmacol. 2023 Jun 21;14:1170591. doi: 10.3389/fphar.2023.1170591. eCollection 2023.
In recent years, Immune checkpoint inhibitors have been extensively used in the treatment of a variety of cancers. However, the response rates ranging from 13% to 69% depending on the tumor type and the emergence of immune-related adverse events have posed significant challenges for clinical treatment. As a key environmental factor, gut microbes have a variety of important physiological functions such as regulating intestinal nutrient metabolism, promoting intestinal mucosal renewal, and maintaining intestinal mucosal immune activity. A growing number of studies have revealed that gut microbes further influence the anticancer effects of tumor patients through modulation of the efficacy and toxicity of immune checkpoint inhibitors. Currently, faecal microbiota transplantation (FMT) have been developed relatively mature and suggested as an important regulator in order to enhance the efficacy of treatment. This review is dedicated to exploring the impact of differences in flora composition on the efficacy and toxicity of immune checkpoint inhibitors as well as to summarizing the current progress of FMT.
近年来，免疫检查点抑制剂已广泛应用于多种癌症的治疗。然而，根据肿瘤类型不同，其有效率在13%至69%之间，且免疫相关不良事件的出现给临床治疗带来了重大挑战。作为一个关键的环境因素，肠道微生物具有多种重要的生理功能，如调节肠道营养代谢、促进肠黏膜更新以及维持肠黏膜免疫活性。越来越多的研究表明，肠道微生物通过调节免疫检查点抑制剂的疗效和毒性，进一步影响肿瘤患者的抗癌效果。目前，粪便微生物群移植（FMT）已发展得相对成熟，并被认为是提高治疗效果的重要调节剂。本综述致力于探讨菌群组成差异对免疫检查点抑制剂疗效和毒性的影响，并总结FMT的当前进展。
